ArticleCase reports in dentistry2026
Cannabinoid Therapy for Refractory Trigeminal Neuropathic Pain: Quantification of Somatosensory Alterations (QualST) by 3D Stereophotogrammetry-Two Case Reports.
Article in Case reports in dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trigeminal neuropathic pain (TNP) is a chronic and debilitating condition frequently resistant to conventional pharmacological therapies. Although cannabinoids have emerged as a potential adjunctive treatment, objective clinical documentation of their effects in orofacial neuropathic pain remains limited. Case Reports: We report two female patients with refractory TNP-one post-traumatic and one idiopathic-who experienced insufficient relief despite trials of anticonvulsants, antidepressants, topical agents, and local interventions. Both patients received a balanced tetrahydrocannabinol (THC):cannabidiol (CBD) sublingual formulation (20 mg/mL each) following a structured titration protocol and were monitored over 8 weeks. Outcomes were assessed using the Douleur Neuropathique 4 Questions (DN4), the visual analog scale (VAS), the World Health Organization Quality of Life-BREF (WHOQOL-Bref), and qualitative sensory testing (QualST). Additionally, three-dimensional facial stereophotogrammetry was employed to objectively quantify areas of hyperfunction and allodynia. Treatment resulted in a marked analgesic response (VAS reduction from 9 to 4 and from 10 to 2), qualitative changes in pain phenotype-from shock-like to predominantly burning-and functional improvement in mastication and oral hygiene. Stereophotogrammetry demonstrated a substantial reduction in sensitized regions, with extraoral hyperfunctional area decreasing from 113.72 to 27.54 cm Conclusion: These cases illustrate the potential clinical relevance of cannabinoids as an adjunctive approach for refractory TNP and highlight the importance of multidimensional assessment strategies. The findings should be interpreted cautiously given the descriptive nature of case reports; however, they underscore the need for controlled studies to further investigate the efficacy and safety of cannabinoid-based therapies in orofacial neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.